Madurai News

Paroxysmal Nocturnal Hemoglobinuria Market: Industry Analysis, Treatment, Pipeline Drugs & Key Companies including Apellis Pharmaceuticals, Roche, Novartis, Alexion Pharmaceutical | DelveInsight

 Breaking News
  • No posts were found

Paroxysmal Nocturnal Hemoglobinuria Market: Industry Analysis, Treatment, Pipeline Drugs & Key Companies including Apellis Pharmaceuticals, Roche, Novartis, Alexion Pharmaceutical | DelveInsight

July 28
02:22 2021
Paroxysmal Nocturnal Hemoglobinuria Market: Industry Analysis, Treatment, Pipeline Drugs & Key Companies including Apellis Pharmaceuticals, Roche, Novartis, Alexion Pharmaceutical | DelveInsight

Paroxysmal Nocturnal Hemoglobinuria Market

Paroxysmal Nocturnal Hemoglobinuria treatment has majorly been symptomatic and non-specific. Practices like an iron replacement, folic acid replenishment, blood transfusion and infection care have been in trend. Corticosteroids (e.g.prednisone) or anticoagulants (e.g. warfarin) are recommended in many cases to suppress the symptoms and to enhance the overall health of patients, but the needed steroid dose is too high to permit its daily use.

 

DelveInsight’s Paroxysmal Nocturnal Hemoglobinuria Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Paroxysmal Nocturnal Hemoglobinuria, historical and forecasted epidemiology as well as the Paroxysmal Nocturnal Hemoglobinuria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some Facts of Paroxysmal Nocturnal Hemoglobinuria Market Report are:

  • The market size of Paroxysmal nocturnal hemoglobinuria in the seven major markets was found to be USD 358.04 million in 2020.
  • The total prevalent population of Paroxysmal nocturnal hemoglobinuria in the 7MM countries was estimated to be 8,385 cases in 2020.
  • Among the European countries, Germany had the highest diagnosed population of PNH with 1,280 cases, followed by the United Kingdom which had 1,055 cases in 2020. On the other hand, Spain had the lowest number of cases as 199 cases in 2020.
  • PNH is a rare condition and is thought to affect around 16 people/million in the United Kingdom.
  • As per the estimates by DelveInsight, the PNH prevalence is higher in the females and overall male and female cases are subjected to an increase in the coming years.

 

Request for free sample report: https://www.delveinsight.com/sample-request/paroxysmal-nocturnal-hemoglobinuria-market

 

Paroxysmal Nocturnal Hemoglobinuria Report Highlights:

  • Paroxysmal Nocturnal Hemoglobinuria market report covers a descriptive overview and comprehensive insight of the PNH epidemiology and Paroxysmal Nocturnal Hemoglobinuria market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  • Paroxysmal Nocturnal Hemoglobinuria market report provides insights on the current and emerging therapies.
  • PNH market report provides a global historical and forecasted market covering drug outreach in 7 MM.
  • Paroxysmal Nocturnal Hemoglobinuria market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the PNH market.

 

Paroxysmal Nocturnal Hemoglobinuria treatment can be grouped into three approaches i.e. Supportive Treatments and immunosuppressive treatments, Treatment changing the course of the disease, and Potential Curative Treatment.

 

Request for free sample report: https://www.delveinsight.com/sample-request/paroxysmal-nocturnal-hemoglobinuria-market

 

The key players in Paroxysmal Nocturnal Hemoglobinuria market that are involved in developing therapies for PNH treatment are:-

  1. Apellis Pharmaceuticals
  2. Hoffmann-La Roche
  3. Novartis
  4. Alexion Pharmaceutical
  5. Regeneron Pharmaceuticals
  6. Achillion Pharmaceuticals
  7. Akari Therapeutics
  8. RA Pharmaceuticals
  9. And many others

 

Paroxysmal Nocturnal Hemoglobinuria Therapies involved are:-

  1. APL-2
  2. Crovalimab
  3. LNP023
  4. ALXN2040
  5. Pozelimab
  6. ACH-0144471
  7. Coversin
  8. RA101495
  9. And many others

 

Table of contents

1. Key Insights

2. Executive Summary of Paroxysmal Nocturnal Hemoglobinuria

3. Competitive Intelligence Analysis for Paroxysmal Nocturnal Hemoglobinuria

4. Paroxysmal Nocturnal Hemoglobinuria: Market Overview at a Glance

5. Paroxysmal Nocturnal Hemoglobinuria: Disease Background and Overview

6. Patient Journey

7. Paroxysmal Nocturnal Hemoglobinuria Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Paroxysmal Nocturnal Hemoglobinuria Treatment

11. Marketed Products

12. Emerging Therapies

13. Paroxysmal Nocturnal Hemoglobinuria: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Paroxysmal Nocturnal Hemoglobinuria

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About DelveInsight:

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-market